ferric reductase Inhibitors
1 drugsAbout ferric reductase
Ferric reductase is an enzyme that reduces ferric iron (Fe3+) to ferrous iron (Fe2+), which is essential for iron absorption, transport, and utilization within the body.
Ferric reductase represents a potential drug target due to its role in iron metabolism, but currently there is no genetic evidence directly linking it to specific diseases.
There is one FDA-approved drug, AURYXIA, a small molecule targeting ferric reductase, marketed by KERYX BIOPHARMS for 'other' therapeutic areas since 2014.
Top ferric reductase Drugs
KERYX BIOPHARMS is the only company with an approved drug targeting ferric reductase.
Low competition suggests potential for market entry, but also indicates higher risk.
ferric reductase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets ferric reductase, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel therapeutic approaches.
ferric reductase Clinical Trials 24 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on ferric reductase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 3 | 2 | 0 | 1 | 100% |
| Phase 3 | 14 | 11 | 1 | 1 | 92% |
| Phase 4 | 6 | 4 | 1 | 1 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
ferric reductase Drug Approval Timeline (2014 - 2014)
AURYXIA was first approved in 2014 and remains the only approved drug.
The stagnant approval timeline suggests market saturation or challenges in target validation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 13 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on ferric reductase. A trial counts if an approved drug acting on ferric reductase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.